This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/30/2023 12:56 PM

BUY Suprajit Engineering

Weak Q2; longer-term growth outlook intact

Auto & Auto Ancillaries > Result Update > November 12, 2023

Suprajit Engineering Limited's (SEL) Q2 performance was a miss, with margins declining by 67bps QoQ to 9.8% (Emkay est. 10.8%). We believe while the global-facing business (particularly non-autos) may remain weak in the near term i) market share gains owing to competitive pricing/scale and industry consolidation, ii) growth in content per vehicle (led by new products), iii) healthy order wins and iv) cyclical recovery in domestic 2Ws would drive ~10% revenue CAGR in FY23-26E. We have cut FY24E/FY25E/FY26E EPS by ~13%/~8%/~2% on weak Q2 margins and soft non-auto exports outlook for the next few quarters. We retain our BUY rating with a revised TP of Rs460 at 18x its FY26E EPS (rolled-over). Key risks: Lower-than-expected growth in underlying segments and adverse movement in currency/commodity prices.

Suprajit Engineering:	Financial	Snapshot (Consolidate	ed)	
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	18,405	27,524	28,588	32,489	37,127
EBITDA	2,599	3,126	3,373	4,564	5,512
Adj. PAT	1,614	1,521	1,810	2,814	3,503
Adj. EPS (Rs)	11.7	11.0	13.1	20.3	25.3
EBITDA margin (%)	14.1	11.4	11.8	14.0	14.8
EBITDA growth (%)	9.8	20.3	7.9	35.3	20.8
Adj. EPS growth (%)	22.6	(12.1)	19.0	55.5	24.5
RoE (%)	15.6	13.2	14.0	19.0	20.3
RoIC (%)	15.0	12.8	12.1	17.0	19.9
P/E (x)	31.5	33.5	28.1	18.1	14.5
EV/EBITDA (x)	19.1	16.6	15.1	10.9	8.7
P/B (x)	4.7	4.2	3.7	3.2	2.7
FCFF yield (%)	2.6	2.8	3.3	3.9	5.2

Source: Company, Emkay Research

Gross margin deterioration impacts sequential EBITDA

Revenue declined by 1% YoY to ~Rs7.1bn; on a segmental basis, Suprajit Controls Division (SCD; comprises automotive and non-automotive exports from India and businesses outside India) reported a ~5% decline, while Phoenix Lamps Division's (PLD) revenue growing 8%. Consolidated EBITDA fell ~11% YoY to Rs698mn, with margins down 67bps QoQ to 9.8% (Emkay est.:10.7%) amid ~180bps gross margin deterioration. SCD reported a 374bps QoQ margin decline to 3.4%, while the domestic cables division's (DCD) margins fell 110bps QoQ to 16.6%. PLD's margins grew strongly by 483bps QoQ to 12.3%. Reported PAT declined by ~24% YoY to Rs348mn (below estimates), with the miss being largely on account of lower-than-expected EBITDA.

Earnings call KTAs

1) The domestic commuter 2W segment is yet to pick up, though signs of positivity are being witnessed in the festive season; the domestic business has been strong so far in Q3, providing confidence for the remaining H2; SCD prospects remain challenged for the remaining part of FY24E, though DCD and PLD are expected to do well; longer-term growth visibility remains intact, led partly by consolidation of auto component suppliers globally; 2) Management expects adverse macros and climatic conditions in the U.S. to continue imparting pressure on the non-auto business in particular (amid weakness in non-discretionary spends for lawn mowers, etc.) for the coming few quarters; European markets are still unstable, though Suprajit continues to register healthy business wins; 3) While auto exports are healthy (e.g., 4W cables), there is postponement of demand at the customer-end due to tough macros (across auto and non-auto); non-auto margins in particular are unlikely to see much improvement during H2; 4) Suprajit's offering of the U.S./Europe front-end with back-end in India is seeing good traction; the company is looking at moving production of certain parts to India to improve profitability; 5) Suprajit Electronics Division (SED) turned EBITDA positive within the first year of operations; started supplying actuators to large E-2W customers with digital clusters also seeing increased traction; 6) FY24E capex guidance unchanged at Rs1.4bn.



Ticker

TARGET PRICE (Rs): 460

Target Price – 12M	Sep-24
Change in TP (%)	4.5
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	25.0
CMP (10-Nov-23) (Rs)	368.0

Stock Data

otoen butu	menter
52-week High (Rs)	447
52-week Low (Rs)	315
Shares outstanding (mn)	138.4
Market-cap (Rs bn)	51
Market-cap (USD mn)	611
Net-debt, FY24E (Rs mn)	51
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	77.5
ADTV-3M (USD mn)	0.9
Free float (%)	55.4
Nifty-50	19,425
INR/USD	83.3
Shareholding, Sep-23	
Promoters (%)	44.6
FPIs/MFs (%)	4.8/15.9

Price Performance								
(%)	1M	3M	12M					
Absolute	(6.0)	(9.6)	12.4					
Rel. to Nifty	(4.7)	(9.1)	4.3					



Jaimin Desai

jaimin.desai@emkayglobal.com +91 22 6612 1334

Chirag Jain

chirag.jain@emkayglobal.com +91 22 6624 2428

Vijay Naraharisetty

vijay.naraharisetty@emkayglobal.com +91 22 6612 1306

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/30/2023 12:56 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO-Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Ir	ndia Equity	Research	Result	Update

Rs mn	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)
Revenue	6,452	7,161	6,921	6,990	6,797	7,089	(1.0)	4.3
Expenditure	5,912	6,374	6,112	6,119	6,082	6,391	0.3	5.1
As a % of sales	91.6	89.0	88.3	87.5	89.5	90.2		
Consumption of RM	3,847	4,336	4,080	3,907	3,906	4,201	(3.1)	7.6
As a % of sales	59.6	60.5	58.9	55.9	57.5	59.3		
Employee Cost	1,428	1,443	1,389	1,484	1,535	1,565	8.4	1.9
As a % of sales	22.1	20.2	20.1	21.2	22.6	22.1		
Other expenditure	638	595	643	728	641	625	5.1	(2.5)
As a % of sales	9.9	8.3	9.3	10.4	9.4	8.8		
EBITDA	540	787	809	871	715	698	(11.3)	(2.4)
EBITDA Margin (%)	8.4	11.0	11.7	12.5	10.5	9.8		
Depreciation	237	239	247	231	247	257	7.5	4.2
EBIT	303	548	562	640	468	441	(19.5)	(5.8)
Other Income	181	217	52	56	129	187	(13.8)	45.6
Interest	61	77	104	115	118	136	77.4	16.0
РВТ	423	688	510	581	479	492	(28.5)	2.7
Total Tax	150	231	129	171	148	145	(37.4)	(2.5)
Minority Interest/Associate Share								
Adjusted PAT	273	457	380	410	331	348	(24.0)	5.0
Extraordinary Items Loss/(Gain)	0	0	0	0	0	0		
Reported PAT	273	457	380	410	331	348	(24.0)	5.0
Adjusted EPS (Rs)	2.0	3.3	2.7	3.0	2.4	2.5	(24.0)	5.0
Margins (%)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (bps)	QoQ (bps)
EBIDTA	8.4	11.0	11.7	12.5	10.5	9.8	(114)	(67)
EBIT	4.7	7.6	8.1	9.2	6.9	6.2	(143)	(67)
EBT	6.6	9.6	7.4	8.3	7.1	6.9	(267)	(11)
PAT	4.2	6.4	5.5	5.9	4.9	4.9	(149)	3
Effective Tax rate	35.5	33.5	25.4	29.4	30.9	29.4	(416)	(155)

Exhibit 2: Actual vs. Estimates (Q2FY24)

(Rs mn)	Actual	Emkay Est	% variance	Consensus	% variance
Net sales	7,089	6,933	2.2	7,256	(2.3)
EBITDA	698	742	(5.9)	837	(16.6)
EBITDA margin (%)	9.8	10.7	-85 bps	11.5	-169 bps
Adj. net income	348	396	(12.3)	387	(10.3)
FDEPS (Rs)	2.5	2.9	(12.3)	2.8	(10.3)

Source: Company, Emkay Research

FY26E

37,127

5,512

14.8

5,181

14.0

248

9.4

25.3

1,400

3.8

3,503

Segmental revenue (Rs mn)	Q2FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)
Suprajit Controls Division	3,430	3,494	3,244	(5)	(7)
Domestic Cable Division	2,820	2,398	2,795	(1)	17
Phoenix Lamps Division	910	877	980	8	12
Suprajit Electronics Division	28	28	70	150	150
Segmental EBITDA (Rs mn)	Q2FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)
Suprajit Controls Division	233	250	111	(52)	(56)
Domestic Cable Division	486	423	463	(5)	ç
Phoenix Lamps Division	68	70	121	77	72
Suprajit Electronics Division	(0)	(0)	4	(902)	(902)
Segmental margins (%)	Q2FY23	Q1FY24	Q2FY24	YoY (bps)	QoQ (bps)
Suprajit Controls Division	6.8	7.2	3.4	(338)	(374)
Domestic Cable Division	17.2	17.7	16.6	(67)	(110)
Phoenix Lamps Division	7.5	8.0	12.3	483	429
Suprajit Electronics Division	-1.6	-1.6	5.1	665	665

Source: Company, Emkay Research

Exhibit 4: Revenue model: We build ~10%/~32% revenue/PAT CAGR over FY23-26E Rs mn FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24E FY25E Revenue 12,028 14,311 15,899 15,628 16,409 18,405 27,524 28,588 32,489 EBITDA 2,020 2,366 2,328 2,187 2,367 2,599 3,126 3,373 4,564 EBITDA margin (%) 16.8 14.6 14.0 11.4 16.5 14.4 14.1 11.8 14.0 EBIT 2,091 2,236 2,298 1,896 2,136 2,380 2,558 3,030 4,234 EBIT margin (%) 17.4 15.6 14.5 12.1 13.0 12.9 9.3 10.6 13.0 Interest 291 271 246 227 192 145 356 481 271 PAT 1,295 1,416 1,338 1,381 1,427 1,614 1,521 1,810 2,814 PAT margin (%) 10.8 9.9 8.4 8.8 8.7 8.8 5.5 6.3 8.7 EPS (Rs.) 10.1 9.6 10.2 11.7 11.0 13.1 20.3 9.3 9.9 Capex 1,348 211 677 1,155 309 540 3,226 1,400 1,400 1.5 As a % of sales 11.2 4.3 7.4 1.9 2.9 4.9 11.7 4.3

Source: Company, Emkay Research

Exhibit 5: We have cut our FY24E/FY25E EPS to reflect weak Q2 margins and soft non-auto exports outlook for the next few quarters

Dama	FY24E			FY25E			FY26E					
Rs mn	Earlier	Revised	Change (%)	YoY (%)	Earlier	Revised	Change (%)	YoY (%)	Earlier	Revised	Change (%)	YoY (%)
Revenue	29,953	28,588	(4.6)	3.9	33,773	32,489	(3.8)	13.6	37,644	37,127	(1.4)	14.3
EBITDA	3,683	3,373	(8.4)	7.9	4,899	4,564	(6.8)	35.3	5,592	5,512	(1.4)	20.8
Margin (%)	12.3	11.8	-50 bps	44 bps	14.5	14.0	-46 bps	225 bps	14.9	14.8	-1 bps	80 bps
Net Profit	2,084	1,810	(13.1)	19.0	3,073	2,814	(8.4)	55.5	3,583	3,503	(2.2)	24.5
EPS (Rs)	15.1	13.1	(13.1)	19.0	22.2	20.3	(8.4)	55.5	25.9	25.3	(2.2)	24.5

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/30/2023 12:56 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

India Equity Research | Result Update

Suprajit Engineering: Consolidated Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	18,405	27,524	28,588	32,489	37,127
Revenue growth (%)	12.2	49.5	3.9	13.6	14.3
EBITDA	2,599	3,126	3,373	4,564	5,512
EBITDA growth (%)	9.8	20.3	7.9	35.3	20.8
Depreciation & Amortization	585	955	1,016	1,075	1,124
EBIT	2,014	2,172	2,356	3,489	4,388
EBIT growth (%)	11.9	7.8	8.5	48.1	25.8
Other operating income	0	0	0	0	0
Other income	366	386	674	745	794
Financial expense	145	356	481	271	248
РВТ	2,235	2,202	2,549	3,963	4,933
Extraordinary items	116	0	0	0	0
Taxes	621	681	739	1,149	1,431
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	1,731	1,521	1,810	2,814	3,503
PAT growth (%)	21.3	(12.1)	19.0	55.5	24.5
Adjusted PAT	1,614	1,521	1,810	2,814	3,503
Diluted EPS (Rs)	11.7	11.0	13.1	20.3	25.3
Diluted EPS growth (%)	22.6	(12.1)	19.0	55.5	24.5
DPS (Rs)	2.0	2.3	2.7	4.3	5.3
Dividend payout (%)	16.0	20.9	20.9	20.9	20.9
EBITDA margin (%)	14.1	11.4	11.8	14.0	14.8
EBIT margin (%)	10.9	7.9	8.2	10.7	11.8
Effective tax rate (%)	27.8	30.9	29.0	29.0	29.0
NOPLAT (pre-IndAS)	1,455	1,500	1,673	2,477	3,115
Shares outstanding (mn)	138.4	138.4	138.4	138.4	138.4

Balance Sheet					
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	138	138	138	138	138
Reserves & Surplus	10,701	12,106	13,538	15,763	18,532
Net worth	10,840	12,245	13,676	15,901	18,671
Minority interests	0	0	0	0	C
Deferred tax liability (net)	554	607	610	614	619
Total debt	3,115	6,417	5,606	5,226	4,707
Total liabilities & equity	14,509	19,269	19,892	21,741	23,996
Net tangible fixed assets	3,511	4,663	5,122	5,446	C
Net intangible assets	702	1,161	1,161	1,161	C
Net ROU assets	402	887	887	887	C
Capital WIP	102	278	203	203	203
Goodwill	1,261	1,364	1,364	1,364	1,364
Investments [JV/Associates]	31	25	25	25	25
Cash & equivalents	4,467	5,495	5,554	6,446	7,586
Current assets (ex-cash)	6,909	10,473	10,915	12,426	14,168
Current Liab. & Prov.	2,877	5,076	5,338	6,217	7,120
NWC (ex-cash)	4,033	5,397	5,576	6,209	7,049
Total assets	14,509	19,269	19,892	21,741	23,996
Net debt	(1,352)	922	51	(1,220)	(2,879)
Capital employed	14,509	19,269	19,892	21,741	23,996
Invested capital	9,909	13,472	14,110	15,067	16,183
BVPS (Rs)	78.3	88.5	98.8	114.9	134.9
Net Debt/Equity (x)	(0.1)	0.1	0.0	(0.1)	(0.2)
Net Debt/EBITDA (x)	(0.5)	0.3	0.0	(0.3)	(0.5)
Interest coverage (x)	0.1	0.1	0.2	0.1	0.0
RoCE (%)	12.6	11.4	11.6	15.3	17.0

Source: Company, Emkay Research

Cash Flows					
	EV 22	EVac	EV245	EVOES	EVACE
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	2,235	2,202	2,549	3,963	4,933
Others (non-cash items)	484	2,587	1,500	1,355	1,379
Taxes paid	(584)	(847)	(737)	(1,145)	(1,426)
Change in NWC	(435)	(1,551)	(243)	(852)	(990)
Operating cash flow	1,816	2,391	3,070	3,321	3,896
Capital expenditure	(525)	(916)	(1,400)	(1,400)	(1,400)
Acquisition of business	888	(4,886)	(500)	(500)	(500)
Interest & dividend income	2	8	0	0	0
Investing cash flow	365	(5,793)	(1,900)	(1,900)	(1,900)
Equity raised/(repaid)	(591)	0	0	0	0
Debt raised/(repaid)	(43)	2,918	(812)	(380)	(519)
Payment of lease liabilities	(56)	(67)	0	0	0
Interest paid	(150)	(335)	(481)	(271)	(248)
Dividend paid (incl tax)	(275)	(284)	(318)	(379)	(589)
Others	(128)	359	0	0	0
Financing cash flow	(1,242)	2,591	(1,611)	(1,029)	(1,356)
Net chg in Cash	938	(811)	(441)	392	640
OCF	1,816	2,391	3,070	3,321	3,896
Adj. OCF (w/o NWC chg.)	2,251	3,942	3,313	4,173	4,886
FCFF	1,291	1,475	1,670	1,921	2,496
FCFE	1,147	1,128	1,189	1,650	2,248
OCF/EBITDA (%)	69.9	76.5	91.0	72.8	70.7
FCFE/PAT (%)	66.3	74.2	65.7	58.7	64.2
FCFF/NOPLAT (%)	88.7	98.4	99.8	77.6	80.1

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and Key Ratios							
Y/E March	FY22	FY23	FY24E	FY25E	FY26E		
P/E (x)	31.5	33.5	28.1	18.1	14.5		
P/CE(x)	23.2	20.6	18.0	13.1	11.0		
P/B (x)	4.7	4.2	3.7	3.2	2.7		
EV/Sales (x)	2.7	1.9	1.8	1.5	1.3		
EV/EBITDA (x)	19.1	16.6	15.1	10.9	8.7		
EV/EBIT(x)	24.6	23.9	21.6	14.2	11.0		
EV/IC (x)	5.0	3.8	3.6	3.3	3.0		
FCFF yield (%)	2.6	2.8	3.3	3.9	5.2		
FCFE yield (%)	2.3	2.2	2.3	3.2	4.4		
Dividend yield (%)	0.5	0.6	0.7	1.2	1.4		
DuPont-RoE split							
Net profit margin (%)	8.8	5.5	6.3	8.7	9.4		
Total asset turnover (x)	1.3	1.6	1.5	1.6	1.6		
Assets/Equity (x)	1.4	1.5	1.5	1.4	1.3		
RoE (%)	15.6	13.2	14.0	19.0	20.3		
DuPont-RoIC							
NOPLAT margin (%)	7.9	5.4	5.9	7.6	8.4		
IC turnover (x)	0.0	0.0	0.0	0.0	0.0		
RoIC (%)	15.0	12.8	12.1	17.0	19.9		
Operating metrics							
Core NWC days	80.0	71.6	71.2	69.8	69.3		
Total NWC days	80.0	71.6	71.2	69.8	69.3		
Fixed asset turnover	2.2	2.7	2.3	2.3	2.4		
Opex-to-revenue (%)	27.3	29.9	30.7	29.7	28.5		

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 11/30/2023 12:56 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
15-Aug-23	401	440	Buy	Chirag Jain
30-May-23	390	460	Buy	Chirag Jain

RECOMMENDATION HISTORY - TREND



Source: Company, Emkay Research

Source: Bloomberg, Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 11/30/2023 12:56 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 11/30/2023 12:56 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of November 12, 2023
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 12, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the November 12, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 11/30/2023 12:56 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.